INCHEON, Korea, November 11, 2025--(BUSINESS WIRE)--Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of ...
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research ...
Samsung Epis Holdings announced Tuesday that it has established a new subsidiary, Epis NexLab, to seek new growth engines by developing biotechnology platforms. The launch of Epis NexLab, whose name ...
Samsung Bioepis Holdings said on the 11th that it established a subsidiary, EPIS NexLab, to pursue new future growth in bio. EPIS NexLab plans to push ahead with developing a bio-technology platform ...
Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO. Byooviz is indicated for the treatment of ...
Samsung Bioepis Holdings, which was spun off from Samsung Biologics, was relisted on the Korea Exchange on the 24th. The industry sees this partitioning and reorganization as "the starting point of ...
Samsung Epis Holdings Co., Ltd. announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexLab will ...
Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform INCHEON, ...
Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings, announced a research collaboration and license agreement with G2GBIO, a company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results